ITRAMIDE™-S

Therapeutic Segment:
Anti-cholinergics

Generic Name:
Ipratropium Bromide/ Salbutamol

Description:
Ipratropium Bromide has anticholinergic (parasympatholytic) properties. It inhibits vagally mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. The bronchodilation following inhalation of Ipratropium Bromide primarily local and site specific to the lung and not systemic in nature. Salbutamol is a beta2-adrenergic agonist, which acts on airway smooth muscle resulting in relaxation. Salbutamol relaxes all smooth muscle from the trachea to the terminal bronchioles and protects against bronchoconstrictor challenges. Ipratropium and salbutamol respules provide the simultaneous delivery of ipratropium bromide and salbutamol sulfate producing effects on both muscarinic and beta2-adrenergic receptors in the lung. This provides increased bronchodilation over that provided by each agent singly.

Indication:
For the management of bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD) who require regular treatment with both ipratropium bromide and salbutamol.

Formulation:

• Inhalation Solution

Strength:

• 0.5mg+2.5mg/2.5ml

Pack Size:

• 10’s